Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00075231
Status:
COMPLETED
Last Update Posted:
2006-10-02
First Post:
2004-01-06
Brief Title:
A Simplified Kaletra LopinavirRitonavir-Based Therapy Versus a Sustiva Efavirenz-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
A Randomized Open-Label Study Exploring a Simplified Kaletra LopinavirRitonavir-Based Therapy Versus a Sustiva Efavirenz-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether a simplified lopinavir-ritonavir based therapy will continue to keep the viral load to very low levels after initial treatment with a combination of Kaletra lopinavirritonavir plus Combivir lamivudinezidovudine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None